COSTA MESA, Calif.--(BUSINESS WIRE)--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced that grants awarded by the Department of Defense to study clinical applications for Oxycyte® total more than $5.3 million. Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier.
